Masimo (NASDAQ:MASI) Earns Buy Rating from BTIG Research

Masimo (NASDAQ:MASI)‘s stock had its “buy” rating restated by investment analysts at BTIG Research in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $198.00 price objective on the medical equipment provider’s stock. BTIG Research’s price target would indicate a potential upside of 32.88% from the company’s current price.

Several other research firms have also commented on MASI. Zacks Research lowered shares of Masimo from a “strong-buy” rating to a “hold” rating in a report on Friday, October 24th. Piper Sandler raised their target price on shares of Masimo from $200.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 6th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Masimo in a report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Masimo from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Masimo currently has an average rating of “Moderate Buy” and a consensus target price of $194.60.

Masimo Price Performance

MASI stock opened at $149.01 on Wednesday. The company has a quick ratio of 1.61, a current ratio of 2.14 and a debt-to-equity ratio of 0.57. Masimo has a 12 month low of $133.70 and a 12 month high of $194.88. The firm has a market cap of $8.09 billion, a P/E ratio of -17.49 and a beta of 1.28. The company’s 50-day moving average price is $144.91 and its two-hundred day moving average price is $154.05.

Masimo (NASDAQ:MASI) last released its earnings results on Thursday, June 20th. The medical equipment provider reported $1.42 EPS for the quarter. Masimo had a negative net margin of 24.85% and a positive return on equity of 26.54%. The firm had revenue of $617.00 million for the quarter. On average, analysts anticipate that Masimo will post 4.1 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Masimo news, Director William R. Jellison bought 3,000 shares of Masimo stock in a transaction on Monday, August 11th. The shares were purchased at an average cost of $145.98 per share, with a total value of $437,940.00. Following the acquisition, the director directly owned 4,790 shares of the company’s stock, valued at $699,244.20. The trade was a 167.60% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 16.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Masimo

Institutional investors have recently added to or reduced their stakes in the business. Nordea Investment Management AB lifted its position in shares of Masimo by 21.6% in the 2nd quarter. Nordea Investment Management AB now owns 31,868 shares of the medical equipment provider’s stock worth $5,330,000 after purchasing an additional 5,659 shares during the period. Strs Ohio acquired a new position in shares of Masimo in the 1st quarter worth approximately $6,686,000. Swedbank AB acquired a new position in shares of Masimo in the 1st quarter worth approximately $12,645,000. Harbor Capital Advisors Inc. acquired a new position in shares of Masimo in the 2nd quarter worth approximately $4,443,000. Finally, Intech Investment Management LLC lifted its position in shares of Masimo by 26.8% in the 1st quarter. Intech Investment Management LLC now owns 32,494 shares of the medical equipment provider’s stock worth $5,414,000 after purchasing an additional 6,872 shares during the period. 85.96% of the stock is owned by institutional investors.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.